115
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Sustained delivery of a camptothecin prodrug – CZ48 by nanosuspensions with improved pharmacokinetics and enhanced anticancer activity

, , , , &
Pages 3799-3817 | Published online: 24 May 2019

References

  • Cao Z, Kozielski A, Liu X, Wang Y, Vardeman D, Giovanella B. Crystalline camptothecin-20(S)-O-propionate hydrate: a novel anticancer agent with strong activity against 19 human tumor xenografts. Cancer Res. 2009;69(11):4742–4749. doi:10.1158/0008-5472.CAN-08-445219458069
  • Cao Z, Harris N, Kozielski A, Vardeman D, Stehlin JS, Giovanella B. Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity. J Med Chem. 1998;41(1):31–37. doi:10.1021/jm96075629438019
  • Botella P, Rivero-Buceta E. Safe approaches for camptothecin delivery: structural analogues and nanomedicines. J Control Release. 2017;247:28–54. doi:10.1016/j.jconrel.2016.12.02328027948
  • Tejpar S, Yan P, Piessevaux H, et al. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: results of the PETACC-3 trial. Eur J Cancer. 2018;99:66–77. doi:10.1016/j.ejca.2018.05.00929909091
  • Ma MK, McLeod HL. Lessons learned from the irinotecan metabolic pathway. Curr Med Chem. 2003;10(1):41–49.12570720
  • Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci. 1992;81(7):676–684.1403703
  • Singh SK, Vaidya Y, Gulati M, Bhattacharya S, Garg V, Pandey NK. Nanosuspension: principles, perspectives and practices. Curr Drug Deliv. 2016;13(8):1222–1246.26721266
  • Wang L, Du J, Zhou Y, Wang Y. Safety of nanosuspensions in drug delivery. Nanomedicine. 2017;13(2):455–469. doi:10.1016/j.nano.2016.08.00727558350
  • Maniam G, Mai CW, Zulkefeli M, Dufès C, Tan DM, Fu JY. Challenges and opportunities of nanotechnology as delivery platform for tocotrienols in cancer therapy. Front Pharmacol. 2018;9:1358. doi:10.3389/fphar.2018.0135830534071
  • Cooper ER. Nanoparticles: a personal experience for formulating poorly water soluble drugs. J Control Release. 2010;141(3):300–302. doi:10.1016/j.jconrel.2009.10.00619822177
  • Pignatello R, Ricupero N, Bucolo C, Maugeri F, Maltese A, Puglisi G. Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene. AAPS PharmSciTech. 2006;7(1):E27. doi:10.1208/pt07012716584158
  • Xiong R, Lu W, Yue P, et al. Distribution of an intravenous injectable nimodipine nanosuspension in mice. J Pharm Pharmacol. 2008;60(9):1155–1159. doi:10.1211/jpp.60.9.000618718118
  • Ganta S, Paxton JW, Baguley BC, Garg S. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int J Pharm. 2009;367(1–2):179–186. doi:10.1016/j.ijpharm.2008.09.02218848873
  • Sarkar M, Grossman RG, Toups EG, Chow DS. Rational design and development of a stable liquid formulation of riluzole and its pharmacokinetic evaluation after oral and IV administrations in rats. Eur J Pharm Sci. 2018;125:1–10. doi:10.1016/j.ejps.2018.09.00430201516
  • Deepika D, Dewangan HK, Maurya L, Singh S. Intranasal drug delivery of frovatriptan succinate-loaded polymeric nanoparticles for brain targeting. J Pharm Sci. 2019;108(2):851–859. doi:10.1016/j.xphs.2018.07.013
  • Attivi D, Wehrle P, Ubrich N, Damge C, Hoffman M, Maincent P. Formulation of insulin-loaded polymeric nanoparticles using response surface methodology. Drug Dev Ind Pharm. 2015;31(2):179–189. doi:10.1081/DDC-200047802
  • Gil EC, Colarte AI, Bataille B, Pedraz JL, Rodríguez F, Heinämäki J. Development and optimization of a novel sustained-release dextran tablet formulation for propranolol hydrochloride. Int J Pharm. 2006;317(1):32–39. doi:10.1016/j.ijpharm.2006.02.04916584856
  • Luo W, Rao M, Qu J, Luo D. Applications of liquid biopsy in lung cancer-diagnosis, prognosis prediction, and disease monitoring. Am J Transl Res. 2018;10(12):3911–3923. Review.30662639
  • Chen Q, Yang Y, Lin X, et al. Platinum(iv) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance. Chem Commun (Camb). 2018;54(42):5369–5372. doi:10.1039/c8cc02791a29744485
  • Han Z, Cao Z, Chatterjee D, Wyche J, Pantazis P. Propionate and butyrate esters of camptothecin and 9-nitrocamptothecin as antileukemia prodrugs in vitro. Eur J Haematol. 1999;62(4):246–255.10227458
  • Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm. 2006;312(1–2):179–186. doi:10.1016/j.ijpharm.2006.01.00816469459
  • Van Eerdenbrugh B, Vermant J, Martens JA. et al. A screening study of surface stabilization during the production of drug nanocrystals. J Pharm Sci. 2009;98(6):2091–2103. doi:10.1002/jps.2156318803265
  • Kostanski JW, DeLuca PP. A novel in vitro release technique for peptide containing biodegradable microspheres. AAPS PharmSciTech. 2000;1(1):E4. doi:10.1208/pt01042714727853
  • Liu X, Wang Y, Vardeman D, Cao Z, Giovanella B. Development and validation of a reverse-phase HPLC with fluorescence detector method for simultaneous determination of CZ48 and its active metabolite camptothecin in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;867(1):84–89. doi:10.1016/j.jchromb.2008.03.013
  • Chow EC, Durk MR, Cummins CL, Pang KS. 1Alpha,25-dihydroxyvitamin D3 upregulates P-glycoprotein via the vitamin D receptor and not farnesoid X receptor in both fxr(-/-) and fxr(+/+) mice and increased renal and brain efflux of digoxin in mice in vivo. J Pharmacol Exp Ther. 2011;337(3):846–859. doi:10.1124/jpet.111.17910121421739
  • Bummer P. Interficial phenomena In: Gennaro A, editor. Remington: The Science and Practice of Pharmacy. 20th ed. Baltimore: Lippincott Williams & Willkins; 2000:285.
  • Van Eerdenbrugh B, Van Den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 2008;364(1):64–75. doi:10.1016/j.ijpharm.2008.07.02318721869
  • Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv. 1995;17(1):31–48. Review. doi:10.1016/0169-409X(95)00039-A
  • Mouton JW, van Peer A, de Beule K, Van Vliet A, Donnelly JP, Soons PA. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob Agents Chemother. 2006;50(12):4096–4102. doi:10.1128/AAC.00630-0616982783
  • Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs–a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol. 2004;113(1–3):151–170. Review. doi:10.1016/j.jbiotec.2004.06.00715380654
  • Li M, Azad M, Davé R, Bilgili E. Nanomilling of drugs for bioavailability enhancement: a holistic formulation-process perspective. Pharmaceutics. 2016;8(2):pii: E17. doi:10.3390/pharmaceutics8020017
  • Möschwitzer JP. Drug nanocrystals in the commercial pharmaceutical development process. Int J Pharm. 2013;453(1):142–156. doi:10.1016/j.ijpharm.2012.09.03423000841
  • Qi YL Impacts of Size on Pharmacokinetics and Biodistributions of Mebendazole Nanoformulation in Mice and Rats. Dissertation University of Houston (2008).
  • Yousif R Microemulsion formulations of CZ48, lactone-stabilized camptothecin-C20- propionate, for transdermal delivery. [ Dissertation]. University of Houston; 2007. doi:10.1094/PDIS-91-4-0467B
  • Hsu JP, Lin MJ. Dissolution of solid particles in liquids. J Colloid Interface Sci. 1993;141:60–66. doi:10.1016/0021-9797(91)90302-O
  • Aulton ME. Pharmaceutics: The Science of Dosage Form Design. Edinburgh: Churchill Livingstone; 2002.
  • Pfuma E Pharmacokinetics and pharmacodynamics of combination CZ48 and manumycin A in an athymic mouse model. [ Ph.D. Dissertation]. University of Houston; 2009.
  • Liu Y, Zhang D, Duan C, et al. Studies on pharmacokinetics and tissue distribution of bifendate nanosuspensions for intravenous delivery. J Microencapsul. 2012;29(2):194–203. doi:10.3109/02652048.2011.64201522172025
  • Kim WY, Nakata B, Hirakawa K. Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy. Cancer Sci. 2007;98(10):1604–1608. doi:10.1111/j.1349-7006.2007.00573.x17683513
  • Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56(11):1649–1659. doi:10.1016/j.addr.2004.02.01415350294
  • Allen TM, Everest JM. Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats. J Pharmacol Exp Ther. 1983;226(2):539–544.6875864
  • Freise J, Müller WH, Magerstedt P. Uptake of liposomes and sheep red blood cells by the liver and spleen of rats with normal or decreased function of the reticuloendothelial system. Res Exp Med (Berl). 1981;178(3):263–269.6165060
  • Peters K, Leitzke S, Diederichs JE, et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother. 2000;45(1):77–83.10629016
  • Burgess DJ. Injectable Dispersed Systems: Formulation, Processing, and Performance. London: Taylor & Francis; 2005.
  • Liehr JG, Harris NJ, Mendoza J, Ahmed AE, Giovanella BC. Pharmacology of camptothecin esters. Ann N Y Acad Sci. 2000;922:216–223. Review.11193897
  • Satoh T, Hosokawa M. The mammalian carboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol. 1998;38:257–288. Review. doi:10.1146/annurev.pharmtox.38.1.2579597156